REFERENCES
1. RIVM: National Institute for Public Health and the Environment. Population screening. Available from: https://www.bevolkingsonderzoeknederland.nl/en/ [Last accessed on 16 August 2022].
2. Health Council of the Netherlands. Population Screening Act (WBO): pilot population screening for lung cancer. The Hague: Gezondheidsraad; 2021. Available from: https://www.healthcouncil.nl/documents/advisory-reports/2021/06/09/population-screening-act-wbo-pilot-population-screening-for-lung-cancer [Last accessed on 16 August 2022].
3. Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ Precis Oncol 2018;2:23.
4. Perrier A, Hainaut P, Guenoun A, et al. Moving towards a personalized oncology: the contribution of genomic techniques and artificial intelligence in the use of circulating tumor biomarkers. Bull Cancer 2022;109:170-84.
5. Cowling T, Loshak H. An overview of liquid biopsy for screening and early detection of cancer. In: CADTH Issues in Emerging Health Technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016. 179.
6. Gadsbøll K, Petersen OB, Gatinois V, et al. NIPT-map Study Group. Current use of noninvasive prenatal testing in Europe, Australia and the USA: a graphical presentation. Acta Obstet Gynecol Scand 2020;99:722-30.
7. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017;17:223-38.
8. Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics 2019;13:34.
9. Hackshaw A, Clarke CA, Hartman AR. New genomic technologies for multi-cancer early detection: rethinking the scope of cancer screening. Cancer Cell 2022;40:109-13.
10. Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol 2020;31:745-59.
11. Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 2020;369:eabb9601.
12. Hackshaw A, Cohen SS, Reichert H, Kansal AR, Chung KC, Ofman JJ. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Br J Cancer 2021;125:1432-42.
13. National Health Service. NHS to pilot potentially revolutionary blood test that detects more than 50 cancers. 27 November 2020. Available from: https://www.england.nhs.uk/2020/11/nhs-to-pilot-potentially-revolutionary-blood-test/ [Last accessed on 16 August 2022].
14. NHS Galleri trial. Clinical resources for GPs. 05 August 2021. Available from: https://www.nhs-galleri.org/about-the-trial/clinical-resources [Last accessed on 16 August 2022].
15. Cochrane AL, Holland WW. Validations of screening procedures. Br Med Bull 1971;27:3-8.
16. Juth N, Munthe C. The Ethics of Screening in Health Care and Medicine: Serving Society or Serving the Patient? Dordrecht, Heidelberg, London, New York: Springer; 2012. Available from: https://link.springer.com/book/10.1007/978-94-007-2045-9 [Last accessed on 16 Aug 2022].
17. Health Council of the Netherlands. Screening. Between hope and hype. The Hague: Gezondheidsraad; 2008. Available from: https://www.healthcouncil.nl/documents/advisory-reports/2008/04/01/screening-between-hope-and-hype [Last accessed on 16 August 2022].
18. Gray JA, Patnick J, Blanks RG. Maximising benefit and minimising harm of screening. BMJ 2008;336:480-3.
19. Haddow J, Palomaki G. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W, editors. Human Genome Epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. New York, Oxford: OUP; 2004. p. 217-33.
20. Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317-9.
21. Serrano MJ, Garrido-Navas MC, Diaz Mochon JJ, et al. International Society of Liquid Biopsy. Precision prevention and cancer interception: the new challenges of liquid biopsy. Cancer Discov 2020;10:1635-44.
22. Putcha G, Gutierrez A, Skates S. Multicancer screening: one size does not fit all. JCO Precis Oncol 2021;5:574-6.
23. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018;359:926-30.
24. Ezell S. Seizing the transformative opportunity of multi-cancer early detection: information technology & innovation foundation (ITIF); 2021. Available from: https://itif.org/publications/2021/04/19/seizing-transformative-opportunity-multi-cancer-early-detection [Last accessed on 16 August 2022].
25. Burke W, Atkins D, Gwinn M, et al. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol 2002;156:311-8.
26. Ozben T. Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry. Clin Chem Lab Med 2013;51:157-76.
27. Jansen ME, Metternick-Jones SC, Lister KJ. International differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents. Eur J Hum Genet 2016;25:10-6.
28. der Meij KRM, Sistermans EA, Macville MVE, et al; Dutch NIPT Consortium. TRIDENT-2: national implementation of genome-wide non-invasive prenatal testing as a first-tier screening test in the Netherlands. Am J Hum Genet 2019;105:1091-101.
29. Kirk EP, Ong R, Boggs K, et al. Gene selection for the Australian Reproductive Genetic Carrier Screening Project (“Mackenzie’s Mission”). Eur J Hum Genet 2021;29:79-87.
30. Remec ZI, Trebusak Podkrajsek K, Repic Lampret B, et al. Next-generation sequencing in newborn screening: a review of current state. Front Genet 2021;12:662254.
31. Dondorp WJ, de Wert GM. The “thousand-dollar genome”: an ethical exploration. Eur J Hum Genet 2013;21 Suppl 1:S6-26.
32. Howard HC, Knoppers BM, Cornel MC, Wright Clayton E, Sénécal K, Borry P. European Society of Human Genetics. , P3G International Paediatric Platform., Human Genome Organisation; and the PHG Foundation. Whole-genome sequencing in newborn screening? Eur J Hum Genet 2015;23:1593-600.
33. Johnston J, Lantos JD, Goldenberg A, Chen F, Parens E, Koenig BA. members of the NSIGHT ethics and policy advisory board. Sequencing newborns: a call for nuanced use of genomic technologies. Hastings Cent Rep 2018;48 Suppl 2:S2-6.
34. Bailey DB Jr, Beskow LM, Davis AM, Skinner D. Changing perspectives on the benefits of newborn screening. Ment Retard Dev Disabil Res Rev 2006;12:270-9.
35. Alexander D, van Dyck PC. A vision of the future of newborn screening. Pediatrics 2006;117:S350-4.
36. Dondorp W, de Wert G, Bombard Y, et al. European Society of Human Genetics. , American Society of Human Genetics. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet 2015;23:1438-50.
37. Loughry L, Pynaker C, White M, Halliday J, Hui L. State-wide increase in prenatal diagnosis of klinefelter syndrome on amniocentesis and chorionic villus sampling: impact of non-invasive prenatal testing for sex chromosome conditions. Prenat Diagn 2022;Online ahead of print.
38. Donley G, Hull SC, Berkman BE. Prenatal whole genome sequencing: just because we can, should we? Hastings Cent Rep 2012;42:28-40.
